世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

デジタルヘルス&人工知能(AI)2020年:動向、市場機会、展望:テレヘルス、テレメディスン、遠隔患者モニタリング、デジタル治療、遺伝子テスト、介護者としてのスマートホーム&医療診断におけるAI

Digital Health & Artificial Intelligence 2020: Trends, Opportunities, and Outlook

Telehealth, telemedicine, remote patient monitoring, digital therapeutics, genetic testing, smart home as a carer & AI in medical diagnostics

 

出版社 出版年月電子版価格 ページ数
IDTechEx
アイディーテックエックス
2020年3月GBP4,650259

※ 調査会社の事情により、予告なしに価格が変更になる場合がございます。
最新の価格はデータリソースまでご確認ください。

サマリー

このレポートはデジタルヘルス市場の主要な動向や市場機会、展望などのエコシステムを下記の項目ごとに分析しています。
  • テレヘルスとテレメディスン
  • 遠隔患者モニタリング
  • デジタル治療(デジセウティカル)、医療デバイスとしてのソフトウェア
  • 糖尿病管理
  • 消費者向け遺伝子テスト
  • 介護者としてのスマートホーム
  • 医療診断におけるAI
 
Report Details
Digital health and artificial intelligence (AI) promises to change the face of healthcare. Reflecting this is growing interest in the digital health space, as evidenced by a substantial growth in investment over the past few years. Major players from the pharmaceutical, medtech, health insurance, retail and technology industries are all forging ahead with investments and internal product development.
 
Digital health is a convoluted and complex field, much of which is made up of technologies and services that enable healthcare outside of traditional clinical settings. It follows a global trend in the healthcare industry of decentralization to alleviate overburdened hospitals and clinics. Coupled with escalating healthcare costs, shrinking profit margins and ageing populations suffering with chronic conditions, digital health offers a solution to these problems for all players in the space including patients, providers and payers. In fact, it presents such an alluring and lucrative opportunity that companies not previously in the healthcare space are making significant investments and moves to do so. Big tech companies such as Amazon, Apple, Alphabet and Microsoft have continued to make significant strides into the healthcare space since their announcements in January 2018.
 
The time is ripe for digital health due to the combination of a number of factors. These include changing population demographics, as well as current and upcoming changes to regulations and reimbursements which mean that the route to market and take-up of digital health services and technologies is more likely. Rising capabilities in artificial intelligence, connectivity and technologies such as continuous glucose monitoring enable new forms of health communication, patient treatment and monitoring, and streamlining of healthcare services.
 
Telemedicine, referring to the remote delivery of healthcare services using technology, is seeing rising demand. Benefits of telemedicine include increased convenience to patients, improved quality of care, improved outcomes, and cost savings. Telemedicine and remote patient monitoring technologies enable patients to leave the hospital earlier and to stay healthy at home for longer. On the other hand, physicians benefit from the broader use of technology in telehealth, including improved communication between practitioners, access to specialists, and even remote training.
 
By whichever name it comes under, whether that's digiceuticals, digital therapeutics or software-as-a-drug, this idea of software replacing drugs is a worry for large, established pharmaceutical companies. Coupled with the changing landscape of healthcare which is moving away from treating patients and towards a model of preventative care and a move from fee-based to value-based services, healthcare delivery is being disrupted and digital health threatens to cause even more turbulence.
 
Artificial intelligence (AI) is revolutionizing medical diagnostics. The state-of-the-art results have already demonstrated that software can achieve fast and accurate image-based diagnostics on various conditions affecting the skin, eye, hear, lung, breast, and so on. These technological advancements can help automate the diagnosis and triage processes, accelerating the process to speed up the referral process especially in urgent cases, freeing up expert resources, offering the best accuracy everywhere regardless of skill levels, and making the processes more widely available. This is a ground-breaking development with far-reaching consequences. Naturally, many innovators are scrambling to capitalize on these advancements.
 
This report outlines the state-of-the-art in AI-based diagnosis of various conditions affecting the skin, eye, heart, breast, brain, lung, blood, genetic disorder, and so. The data sources employed are diverse including dermoscopic images, fundus images, OCT, CT, CTA, echocardiograms, electrocardiogram , mammography, pathology slides, low-res mobile phone pictures, and so on. This report then identifies and highlights companies seeking to capitalize on these technology advances to automate the diagnostic and triage process.
 
This report provides a detailed overview of the digital health ecosystem including insights into the key trends, opportunities and outlooks for all aspects of digital health, including:
• Telehealth and telemedicine
• Remote patient monitoring
• Digital therapeutics / digiceuticals / software as a medical device
• Diabetes management
• Consumer genetic testing
• Smart home as a carer
• AI in diagnostics


目次

Table of Contents

1. EXECUTIVE SUMMARY & CONCLUSIONS
1.1. The Scope of Digital Health
1.2. Changing Demographics Require Healthcare Reforms
1.3. Factors Encouraging the Rise of Digital Health
1.4. Enabling Technologies for Digital Health
1.5. Effective Use of Resources Enabling Cost Efficiency
1.6. The Future of Healthcare is Consumer-Led
1.7. Big Tech Players are Moving into Healthcare
1.8. Towards a Model of Value-Based Healthcare
1.9. Big Pharma is Struggling, Disruption is Inevitable
1.10. Consolidating and Collaborating to Survive and Thrive
1.11. Regulation of Digital Health: Wanting the Best of Both Worlds
1.12. Telehealth and Telemedicine are Poised for Take-Off
1.13. The Future for Telehealth and Telemedicine
1.14. Remote Patient Monitoring is Changing the Face of Healthcare
1.15. The Outlook for Remote Patient Monitoring
1.16. Digital Therapeutics - The Next Step for mHealth?
1.17. The Outlook for Digital Therapeutics
1.18. The Rise of Direct-to-Consumer Genetic Testing
1.19. Sensors in Smart Homes: Decentralization of Healthcare
1.20. Funding and IPOs
1.21. Market Outlook: Wearable Medical Devices
1.22. Outlook for Digital Health: Quality, Outcomes, and Value are Key
2. INTRODUCTION
2.1. The Scope of Digital Health
2.2. Digital Health Definitions
2.3. Changing Demographics Require Healthcare Reforms
2.4. Global Healthcare Spending is Rising
2.5. Margins are Being Squeezed in Healthcare
2.6. Trouble for Traditional Healthcare?
2.7. Mergers and Acquisitions: Vertical Integration
2.8. Big Tech Players are Moving into Healthcare
2.9. Apple - 2018 Update
2.10. Apple - 2019 Update
2.11. Amazon
2.12. Amazon - Alexa
2.13. Alphabet
2.14. Microsoft
2.15. Tencent
2.16. From Fee-for-Service to Value-Based Purchasing
2.17. Towards a Model of Value-Based Healthcare
2.18. Big Pharma is Struggling
2.19. Digital Disruptors & Big Pharma: A Match Made in Heaven?
2.20. Big Pharma: Competitions and Digital Hubs
2.21. The Future for Pharma
2.22. Rising Role of Venture Capital
2.23. Funding and IPOs
2.24. Mobile Health is Becoming the Norm
2.25. Apple Enters the Electronic Health Record Market
2.26. The Future of Healthcare is Consumer-Led
2.27. Apps are Moving Towards Voice
2.28. A Move to Precision/Personalized Medicine
2.29. Biosensors are Moving to the Point-of-Care
2.30. Consumer-Driven, Patient Centered Healthcare
2.31. Global Challenges in Implementing Digital Health
2.32. The P4 Healthcare Model
2.33. The Emergence of a P4 Healthcare System
2.34. Wellness and Prevention
2.35. Market Outlook: Wearable Medical Devices
3. ENABLING TECHNOLOGIES
3.1. Enabling Technologies for Digital Health
3.2. IoT
3.3. 5G
3.4. Access to High Quality Broadband
3.5. Artificial Intelligence and Machine Learning
3.6. VR, AR and MR
4. REGULATIONS AND SECURITY
4.1. Digital vs Traditional Healthcare
4.2. Medical Device Pathways
4.3. Regulation of Digital Therapeutics
4.4. FDA Pre-Cert Program
4.5. Pre-Cert 1.0
4.6. Digital Tools Not Under FDA Review
4.7. Regulation of Direct-to-Consumer Genetic Testing
4.8. Genetic Data, Privacy Concerns and a Lack of Trust
4.9. Unanswered questions about device security
4.10. Security Risks for Medical Devices
4.11. The Security of Data is a Critical Issue
4.12. National Systems at Risk of Large-Scale Cyber Attacks
5. TELEHEALTH & TELEMEDICINE
5.1. Defining Telehealth and Telemedicine
5.2. Telehealth Encompasses a Range of Services
5.3. There are Numerous Types of Telemedicine
5.4. The Key Services Models for Telehealth
5.5. Use Cases for Telehealth and Telemedicine
5.6. Benefits of Telehealth and Telemedicine
5.7. Challenges in Telehealth and Telemedicine
5.8. Is Telehealth a Cost-Effective Solution?
5.9. Telehealth and Telemedicine are Poised for Take-Off
5.10. The Growing Network of Care
5.11. Doctors Require Better Ways of Communication
5.12. Nomadeec
5.13. Smartphones Become the Tool for Doctors
5.14. Driving the Uptake of Telemedicine
5.15. Changes to Reimbursement of Telehealth
5.16. Reimbursement of Remote Patient Monitoring
5.17. Room to Improve and Mature
5.18. The Next-Generation of Telemedicine
5.19. Can AI Replace Your Doctor?
5.20. Babylon Health
5.21. TytoCare
5.22. American Well
5.23. Key American Well Partnerships
5.24. The Future for Telehealth and Telemedicine
5.25. The Future for Telehealth and Telemedicine (cont.)
6. REMOTE PATIENT MONITORING
6.1. Remote Patient Monitoring: Measurements and Applications
 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る